Skip to content
Wenlo
Sign in
← Markets

Anavex Life Sciences Corp.

Sandra Boenisch (PFO & Treasurer) reports AVXL insider transactions

4AVXLFiled Sep 28, 2026, 5:36 PM ET· Period Sep 24, 2026

About this filing

Anavex Life Sciences Corp. (AVXL) filed Form 4 (insider transaction) with the SEC on Sep 28, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Sandra Boenisch · PFO & Treasurer
DateTransactionSharesPriceValueHeld afterOwnership
Sep 24, 2026A · grantStock Option (Right to Buy)Footnotes F1+20,000$0.00$0.0020,000Direct
Sep 24, 2026A · grantStock Option (Right to Buy)Footnotes F1+25,000$0.00$0.0025,000Direct
Sep 24, 2026A · grantStock Option (Right to Buy)Footnotes F1+25,000$0.00$0.0025,000Direct
Sep 24, 2026A · grantStock Option (Right to Buy)Footnotes F1+25,000$0.00$0.0025,000Direct
Footnotes
  1. F1 As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

More AVXL filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.